Akeso's cancer drug, Ivonescimab, has faced a setback as the US Food and Drug Administration (FDA) rejected its application. This led to a significant drop in Akeso's shares, raising concerns about the drug's commercial prospects. Summit Therapeutics, which holds the global rights to Ivonescimab, stated that the drug did not provide sufficient evidence of effectiveness. AI
RANK_REASON Regulatory decision on a specific drug application.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →